Moderna, Inc. (MRNA) Operating income 2016–2025
Moderna, Inc. (MRNA) annual operating income history from SEC filings — each fiscal year as reported.
-$3.1BFY2025 · since FY2016: -$223.8M → -$3.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.1B | +22.1% |
| FY2024 | -$3.9B | +6.9% |
| FY2023 | -$4.2B | -145.0% |
| FY2022 | $9.4B | -29.2% |
| FY2021 | $13.3B | +1842.6% |
| FY2020 | -$763.0M | -39.7% |
| FY2019 | -$546.0M | -32.1% |
| FY2018 | -$413.3M | -53.4% |
| FY2017 | -$269.4M | -20.4% |
| FY2016 | -$223.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MRNA financial trends
MRNA RevenueMRNA Net incomeMRNA Net marginMRNA Gross profitMRNA Gross marginMRNA Operating marginMRNA Operating cash flowMRNA Free cash flowMRNA Capital expendituresMRNA Return on equityMRNA Stock buybacksMRNA Dividends paidMRNA Total assetsMRNA Total liabilitiesMRNA Shareholders’ equityMRNA overview →